Apollomics (APLM)
NASDAQ:APLM
Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$22.52
-$0.28(-2.62%)
At close: 4:00 PM EST
$22.52
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$31.41M
Enterprise Value$12.98M
Total Cash (Recent Filing)$9.77M
Total Debt (Recent Filing)$966.00K
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-54.48
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue65.55
Enterprise Value/Gross Profit65.55
Enterprise Value/Ebitda-0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Oncology FocusApollomics’ focus on small-molecule and precision-medicine candidates for genetically defined cancers represents a durable, specialty-biotech business model. This niche orientation supports differentiated R&D programs, clearer go/no-go decision points, and partnership appeal to pharma over the medium term.
Material Revenue ImprovementA pronounced revenue increase in 2025 indicates emerging commercial or partnership traction rather than pure grant or licensing early receipts. This improvement can provide recurring funding support for R&D, reduce binary dilution risk, and signal validation of assets to collaborators and investors over coming quarters.
Low Absolute Reported DebtReported debt is low in absolute terms, which reduces near-term interest and covenant pressure for a cash-burning biotech. Lower leverage provides flexibility to raise equity or enter partnerships without the added constraint of heavy debt servicing over the medium term.
Bears Say
Persistent Negative Free Cash FlowSustained negative free cash flow of roughly $10M annually means ongoing reliance on external financing to fund trials and operations. This structural cash burn increases dilution and execution risk, and constrains strategic optionality unless durable funding or partnerships are secured.
Negative Stockholders' EquityA shift to negative equity weakens balance-sheet credibility and raises financing risk for a pre-profit biotech. Negative equity can complicate access to capital, increase cost of funding, and reduce lender/investor confidence, making multi-quarter R&D programs harder to sustain without dilution or strategic deals.
Ongoing Unprofitability And Margin UncertaintyLarge operating losses and inconsistent gross profit indicate margins are not yet sustainable. Continued negative EBIT and variable revenue quality increase execution risk on development programs and limit internal reinvestment capacity, necessitating external funding to reach commercialization milestones.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $31.41M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 99 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter, beating the consensus estimate of N/A by $3.795.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,196,052 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.99%
12-Months-Change
Fundamentals
Return on Equity
288.40%
Trailing 12-Months
Asset Growth
-48.74%
Trailing 12-Months
Company Description
Apollomics
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
0.61% Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---